 |
|
|
| |
NOVEL NS5A INHIBITOR ACH-2928 PHASE 1 RESULTS IN HEALTHY VOLUNTEERS AND HCV GT-1 PATIENTS
|
| |
| |
Reported by Jules Levin
EASL 2012
Authors: Vince B1, Lawitz E2, Searle S3, Marbury T4, Robison H5, Robarge L5, and Olek E5
Affiliations: 1Vince and Associates Clinical Research, Overland Park, KS 2Alamo Medical Research, San Antonio, TX,
3Comprehensive Clinical Development, Tacoma, WA, 4Orlando Clinical Research Center, Orlando, FL,
5Achillion Pharmaceuticals Inc., New Haven, CT
CONCLUSIONS
- Oral doses of ACH-2928 up to 500 mg appear to be safe and well-tolerated in healthy volunteers
- Pharmacokinetic profiles support 10 mg and 60 mg dosing regimens in HCV infected patients
- The mean maximum HCV RNA viral load decline of 3.68 log10 observed in the ACH-2928 60 mg QD dose group shows a robust antiviral effect and no virologic breakthrough with monotherapy compared to the placebo arm decline of 0.54 log10
- These results supports continued investigation of ACH-2928 in both PegIFN/RBV and DAA combinations
|
| |
|
|
|
|
|
